This Phase 1 randomized “HIV Cure Study” is evaluating whether ImmunityBio’s immune-enhancer protein N-803 along or together with broadly neutralizing antibodies can control HIV following antiretroviral therapy.

Acceptance Requirements
Adult patients diagnosed with HIV-1 infection
Most have been on ART for at least 96 weeks prior to joining the trial